Chagas Disease, caused by the protozoan parasite Trypanosoma cruzi, affects millions worldwide, yet current therapies suffer from limited efficacy, long treatment duration, and poor tolerability. Two complementary discovery strategies, one mechanism-driven and one phenotypically guided, were explored toward safer, shorter-course treatments. Covalent picolinamides were developed as highly selective inhibitors of ...
